Safety of Corneal Collagen Cross-linking With UV-A and Riboflavin in Progressive Keratoconus

Yakov Goldich, MD,* Arie L. Marcovich, MD,† Yaniv Barkana, MD,* Isaac Avni, MD,* and David Zadok, MD*

Purpose: To assess the possible damage to ocular tissues during treatment of keratoconus with UV-A–riboflavin corneal collagen cross-linking (CXL).

Design: Single center, prospective, interventional study.

Methods: Fourteen eyes of 14 patients aged 28.2 ± 5.9 (mean ± SD) years with progressive keratoconus were treated with UV-A–riboflavin CXL. Corneal endothelium was assessed with the endothelial specular microscope. Central retina was assessed with biomicroscopy fundus examination and with optical coherence tomography using macular thickness protocol. Patients were assessed preoperatively, at week 1, month 1, 3, 6, 9, and 12 after treatment.

Results: Comparative preoperative and postoperative results showed stable endothelial cell density (2730 cells/mm², 2793 cells/mm², and 2640 cells/mm², respectively) and stable foveal thickness (203, 202, and 205 μm, respectively) at month 6, and at month 12, respectively). No morphological abnormalities were noted.

Conclusions: UV-A–riboflavin CXL seems to be a safe procedure that does not cause damage to the corneal endothelium and central retina.

Key Words: keratoconus, corneal collagen cross-linking, UV-A

Cornea 2010;29:409–411

Corneal collagen cross-linking (CXL) using UV-A light and riboflavin has been proposed recently as treatment to halt the progression of keratoconus (KC).1 Treatment effect is reached by increasing covalent bindings between collagen molecules in the anterior corneal stroma. This process is mediated by free radicals generated by photosensitization of riboflavin by UV-A light.1,2 Both photochemically induced free radicals and UV-A irradiation can potentially damage intraocular structures including corneal endothelial cells and human retina.3–6 Therefore, before we accept the UV-A–riboflavin CXL in everyday practice, we must ascertain its safety.

The aim of the current study was to assess in vivo the possible damage to the corneal endothelium and the retina after UV-A–riboflavin CXL treatment.

METHODS

Patients with KC were prospectively recruited from the cornea outpatient clinic of the Assaf Harofeh Medical Center. Inclusion criteria were progressive KC documented clinically within the past 12 months by astigmatic refraction and/or topography, age over 18 years, no previous ocular surgery, no corneal opacities, minimal central corneal thickness of 400 μm, and avoidance of contact lens wear for 1 month before initial evaluation and treatment. Patients were treated with UV-A–riboflavin CXL under aseptic conditions using topical preoperative anesthesia with oxybuprocaine hydrochloride 0.4% drops (Localin; Fisher Pharmaceutical Labs). Treatment included 7-mm-diameter corneal deepithelialization, instillation of 0.1% riboflavin in 20% dextran solution (Peschke Meditrade GmbH, Huenenberg, Switzerland) every 5 minutes for 40 minutes and corneal irradiation with UV-A 3 mW/cm² (UV-X; Peschke Meditrade GmbH) for 30 minutes, 5 cm from the cornea. After the procedure, patients were treated with topical antibiotic (ofloxacin 0.3%, Oflox; Allergan) 4 times a day for 7 days, topical corticosteroid (dexamethasone 0.1%, Sterodex; Fisher Pharmaceutical Labs) 4 times a day for 1 month, and the eye was dressed with a soft therapeutic contact lens (Ocular Sciences, Ltd, Southampton, United Kingdom) for 3 days.

Patients were assessed preoperatively and at week 1, month 1, 3, 6, and 12 after treatment. Each examination included measurement of best spectacle–corrected visual acuity and slit-lamp examination and dilated fundus examination. Corneal topography, pachymetry, endothelial cell density (ECD), central foveal thickness (CFT), and macular morphology (thickness and reflectivity) were assessed. Corneal topography and pachymetry were assessed preoperatively and at months 6, 9, and 12 with Orbscan II (Bausch & Lomb, Claremont, CA). ECD was assessed preoperatively and at months 1, 6, and 12 with the Konan Noncon Robo SP 6000 noncontact specular microscope (Konan Medical, Inc, Hyogo, Japan). CFT and macular morphology were assessed preoperatively and at months 3, 6, 9, and 12 with Stratus optical...
coherence tomography (OCT; Zeiss Humphrey Instruments, Dublin, CA).

The study was approved by the Institutional Ethics Committee of Assaf Harofeh Medical Center, and a written informed consent was obtained from each subject after the nature and intent of the study had been fully explained. The study protocol was consistent with the tenets of the Declaration of Helsinki.

**Statistical Analysis**

The data are presented as frequency or mean ± SD. Paired 2-tailed Student t test was used to assess differences between the compared groups in ECD and CFT. The distributions of values within each data set were evaluated graphically. A P value of 0.05 was selected for the threshold of statistical significance. Analyses were performed using Excel (Microsoft, Corp, Redmond, WA).

**RESULTS**

Fourteen eyes of 14 patients (8 males and 6 females) aged 28.2 ± 5.9 years were included. Study parameters at baseline and 12 months postoperatively are shown in Table 1. Figures 1 and 2 present ECD and CFT measurements during the study period. There were no statistically significant differences between preoperative and postoperative values of ECD and CFT at any follow-up time point.

No macular abnormalities were observed throughout the study period by means of biomicroscopic fundus examination and OCT analysis.

**DISCUSSION**

In the current study, we assessed the safety of treatment of KC using UV-A irradiation in conjunction with riboflavin. Our results show that this procedure does not cause corneal endothelial cell loss or has influence on foveal thickness. The recommended safety criteria, however, must be observed because UV irradiation has potential to damage various intraocular structures.4–6

Based on in vitro studies, Wollensak et al1 recommended the following safety criteria for UV-A-riboflavin CXL: corneal thickness of at least 400 μm, irradiation with 3 mW/cm² UV-A (370 nm), and keeping the cornea constantly covered with riboflavin solution before and during UV irradiation to provide a shielding effect.7 According to Lambert–Beer law, applying riboflavin increases UV-A absorption in the corneal stroma and reduces UV-A transmission through the cornea to about 7%. The endothelial damage threshold was shown to be at an irradiance of 0.35mW/cm², which is approximately twice compared with the 0.18 mW/cm² that reaches the corneal endothelium when using the currently recommended protocol.7,8

Previous human in vivo studies used confocal microscopy9,10 and endothelial specular microscopy1,11 to assess endothelial damage. These studies did not detect any changes in endothelial morphology or density after UV-A-riboflavin CXL. However, different UV-A light sources were used in these studies. Caporossi et al9 and Mazzotta et al10 used CBM X-linker device (CSO, Florence, Italy). The CBM X-linker is

**TABLE 1. Study Parameters and Their Mean Change After Cross-linking**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Before CXL</th>
<th>6 Months After CXL</th>
<th>12 Months After CXL</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCVA (logMAR)</td>
<td>0.21 ± 0.1</td>
<td>0.17 ± 0.1</td>
<td>0.11 ± 0.1</td>
<td>&lt;0.005</td>
</tr>
<tr>
<td>UCVA (logMAR)</td>
<td>0.62 ± 0.5</td>
<td>1.02 ± 0.6</td>
<td>0.78 ± 0.6</td>
<td>0.67</td>
</tr>
<tr>
<td>CFT (μm)</td>
<td>203 ± 21</td>
<td>203 ± 17</td>
<td>205 ± 22</td>
<td>0.78</td>
</tr>
<tr>
<td>ECD (cells/mm²)</td>
<td>2730 ± 261</td>
<td>2793 ± 290</td>
<td>2640 ± 266</td>
<td>0.21</td>
</tr>
<tr>
<td>CCT (μm)</td>
<td>461 ± 38</td>
<td>441 ± 47</td>
<td>478 ± 52</td>
<td>0.84</td>
</tr>
<tr>
<td>Kmax (D)</td>
<td>53.9 ± 5.9</td>
<td>53.1 ± 5.5</td>
<td>52.1 ± 5.0</td>
<td>0.006</td>
</tr>
<tr>
<td>Kmin (D)</td>
<td>44.3 ± 2.6</td>
<td>44.2 ± 3.3</td>
<td>43.7 ± 2.8</td>
<td>0.049</td>
</tr>
<tr>
<td>Mean sim K (D)</td>
<td>46.2 ± 2.8</td>
<td>46.3 ± 3.3</td>
<td>45.6 ± 2.9</td>
<td>0.14</td>
</tr>
</tbody>
</table>

Values are presented as mean ± SD.

BCVA, best-corrected visual acuity with glasses; CCT, central corneal thickness; Kmax, maximal keratometry; Kmin, minimal keratometry; mean sim K, average simulated keratometry; P, t test (12 months after CXL versus before CXL); UCVA, uncorrected visual acuity.

**FIGURE 1.** Box (mean ± SD) and whisker (smallest and largest values) plots showing ECD (cells/mm²) before treatment (Preop) and on 1 month, 6 months, and 12 months thereafter.

**FIGURE 2.** Box (mean ± SD) and whisker (smallest and largest values) plots showing CFT (μm) before treatment (Preop) and on 3, 6, 9, and 12 months thereafter.
a system of 2 diodes, and the new system has 5 diodes that produces UV light at a wavelength of no more than 370 nm. Wollensak et al used a light source with 2 UV diodes (Roithner Lasertechnik, Vienna, Austria) at a distance of 1 cm from the cornea. These original systems that used 2 lights could produce damaging hot spots. Wittig-Silva et al used UV-X system (Peschke Medittrade GmbH, Switzerland), which emits the UV light via a special optical system (Koehler optics) that makes the unit much less responsive to slight variations in illumination distance. This way, the risk of overexposure is minimized. In the UV-X system, 7 light emitting diodes are set in a flower pattern. This gives a very smooth distribution of light over the cornea. In our study, we used only the UV-X illumination source with 7 diodes, and our results show no significant decline in ECD at any time after UV-A–riboflavin treatment with follow-up of 1 year (P = 0.21). Similar stability of ECD was reported by Wittig-Silva et al using similar irradiation system.

Another important aspect is the safety of UV-A–riboflavin treatment to inner eye structures, especially to the lens and the retina. Light injury to the retina may be caused by thermal- or light-induced photochemical damage. Ultraviolet radiation is potentially more hazardous to the retina than other wavelengths. In rabbits, the threshold radiant exposure for retinal damage was shown to be 4.3 mW/cm², which is higher than dose during CXL (3 mW/cm²). In the human eye, the main absorption of the UV-A light is in the crystalline lens and only a small fraction may reach the retina. However, a clear crystalline lens that is characteristic of young patients with KC may be less protecting against such UV penetration. Although in vitro studies showed that the shielding effect of riboflavin limited radiant transmission to inner ocular structures, no previous in vivo studies were conducted to assess retinal morphological changes after UV-A–riboflavin CXL.

Both clinical biomicroscopy fundus examination and OCT may reveal retinal photochemical damage. Retinal photochemical damage has been described as solar retinopathy in patients with a history of sun gazing. Considering that over 90% of the sun’s UV light reaching earth is UV-A light (320–400 nm), we may expect that artificially induced damage from UV-A irradiation during CXL (370 nm) will have similar morphological characteristics to solar retinopathy. OCT was previously shown to be a useful tool in assessing retinal photochemical damage. Various patterns of macular damage after prolonged exposure to solar radiation were described. Garg et al, Stangos et al, and Gulkilik et al described OCT findings in patients with chronic solar retinopathy. They all reported hyporeflective space at the level of the outer neurosensory retina and retinal pigment epithelium with foveal thinning. Bechmann et al described OCT findings in patients with early solar retinopathy and reported a hyperreflective area involving all foveal retinal layers with normal foveal thickness. In our study, all OCT examinations throughout the study period of 1 year presented a normal macula in every studied eye. No changes in macular thickness or in retinal reflectivity in any layer were observed. Clinical funduscopy examinations were unremarkable during every time point, and no morphological changes were noted. Grewal et al recently published 1-year follow-up results after CXL in progressive KC. Using Stratus OCT, they reported a slight decrease of 29 µm in foveal thickness 1 year after cross-linking. Although this change was not statistically significant, its magnitude is different from the practically stable foveal thickness as measured in our study. This suggests that more studies with larger sample size and longer follow-up are required to understand whether this difference is meaningful.

In conclusion, our data suggest that UV-A–riboflavin CXL is a safe procedure for treating progressive KC. When this procedure is performed using currently recommended parameters, no corneal endothelium or retinal structural damage is expected.

REFERENCES